Sökning: onr:"swepub:oai:DiVA.org:uu-343661" >
Dapagliflozin is as...
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy : A multinational observational study
-
- Persson, Frederik (författare)
- Steno Diabet Ctr, Copenhagen, Denmark.
-
- Nystrom, Thomas (författare)
- Karolinska Institutet
-
- Jorgensen, Marit E. (författare)
- Steno Diabet Ctr, Copenhagen, Denmark.
-
visa fler...
-
- Carstensen, Bendix (författare)
- Steno Diabet Ctr, Copenhagen, Denmark.
-
- Gulseth, Hanne L. (författare)
- Oslo Univ Hosp, Oslo, Norway.
-
- Thuresson, Marcus (författare)
- Statisticon AB, Uppsala, Sweden.
-
- Fenici, Peter (författare)
- AstraZeneca, Cambridge, England.
-
- Nathanson, David (författare)
- Karolinska Institutet
-
- Eriksson, Jan W (författare)
- Uppsala universitet,Klinisk diabetologi och metabolism
-
- Norhammar, Anna (författare)
- Karolinska Institutet
-
- Bodegard, Johan (författare)
- AstraZeneca Nord Balt, N-0601 Oslo, Norway.
-
- Birkeland, Kare I. (författare)
- Oslo Univ Hosp, Oslo, Norway.;Univ Oslo, Oslo, Norway.
-
visa färre...
-
Karolinska Institutet Steno Diabet Ctr, Copenhagen, Denmark (creator_code:org_t)
- 2017-09-08
- 2018
- Engelska.
-
Ingår i: Diabetes, obesity and metabolism. - : Wiley. - 1462-8902 .- 1463-1326. ; 20:2, s. 344-351
- Relaterad länk:
-
https://onlinelibrar...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aims To compare the sodium-glucose-cotransporter-2 (SGLT-2) inhibitor dapagliflozin with dipeptidyl peptidase-4 (DPP-4) inhibitors with regard to risk associations with major adverse cardiovascular (CV) events (MACE; non-fatal myocardial infarction, non-fatal stroke or cardiovascular mortality), hospitalization for heart failure (HHF), atrial fibrillation and severe hypoglycaemia in patients with type 2 diabetes (T2D) in a real-world setting.Methods All patients with T2D prescribed glucose-lowering drugs (GLDs) during 2012 to 2015 were identified in nationwide registries in Denmark, Norway and Sweden. Patients were divided into two groups: new users of dapagliflozin and new users of DPP-4 inhibitors, matched 1:3 by propensity score, calculated by patient characteristics, comorbidities and drug treatment. Cox survival models were used to estimate hazard ratio (HR) per country separately, and a weighted average was calculated.Results After matching, a total of 40908 patients with T2D were identified as new users of dapagliflozin (n=10227) or a DPP-4 inhibitor (n=30681). The groups were well balanced at baseline; their mean age was 61years and 23% had CV disease. The mean follow-up time was 0.95years, with a total of 38760 patient-years. Dapagliflozin was associated with a lower risk of MACE, HHF and all-cause mortality compared with DPP-4 inhibitors: HRs 0.79 (95% confidence interval [CI] 0.67-0.94), 0.62 (95% CI 0.50-0.77), and 0.59 (95% CI 0.49-0.72), respectively. Numerically lower, but non-significant HRs were observed for myocardial infarction (0.91 [95% CI 0.72-1.16]), stroke (0.79 [95% CI 0.61-1.03]) and CV mortality (0.76 [95% CI 0.53-1.08]) Neutral associations with atrial fibrillation and severe hypoglycaemia were observed.Conclusions Dapagliflozin was associated with lower risks of CV events and all-cause mortality compared with DPP-4 inhibitors in a real-world clinical setting and a broad T2D population.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Nyckelord
- cardiovascular disease
- dapagliflozin
- diabetes complications
- DPP-4 inhibitor
- hypoglycaemia
- type 2 diabetes
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Persson, Frederi ...
-
Nystrom, Thomas
-
Jorgensen, Marit ...
-
Carstensen, Bend ...
-
Gulseth, Hanne L ...
-
Thuresson, Marcu ...
-
visa fler...
-
Fenici, Peter
-
Nathanson, David
-
Eriksson, Jan W
-
Norhammar, Anna
-
Bodegard, Johan
-
Birkeland, Kare ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
- Artiklar i publikationen
-
Diabetes, obesit ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet